Compare ENTA & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTA | PNNT |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.6M | 397.7M |
| IPO Year | 2012 | 2007 |
| Metric | ENTA | PNNT |
|---|---|---|
| Price | $12.15 | $4.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $20.40 | $5.85 |
| AVG Volume (30 Days) | 147.1K | ★ 732.7K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 20.91% |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.14 |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $4.09 | $4.54 |
| 52 Week High | $17.15 | $7.53 |
| Indicator | ENTA | PNNT |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 38.81 |
| Support Level | $12.09 | N/A |
| Resistance Level | $15.52 | $4.93 |
| Average True Range (ATR) | 0.63 | 0.15 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 7.62 | 28.26 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.